Company news
Polyrizon Ltd. news in 2026
Polyrizon Ltd.'s news releases, calls and decks from 2026, newest first.
Polyrizon Announces Successful Completion Enrollment of all 120 Patients in U.S. Clinical Study of NASARIX Allergy Blocker
October 27, 2026
Polyrizon Files for U.S. Patent Application to Expand IP Moat Around Intranasal Drug-Delivery Platform
October 5, 2026
Polyrizon Enrolls First Patient in U.S. Clinical Study of NASARIX (PL-14) Allergy Blocker
September 22, 2026
Polyrizon Ltd. Announces Closing of $4.0 Million Registered Direct Offering and Private Placement
September 4, 2026
Polyrizon Ltd. Announces $4.0 Million Registered Direct Offering and Private Placement
September 3, 2026
Polyrizon Completes All Five U.S. Site Contracts for NASARIX™ First-in-Human Allergy Study
September 2, 2026
Polyrizon Completes Clinical Site Network for NASARIX™ Study and Advances Toward Patient Enrollment
August 20, 2026
Polyrizon Announces Successful Results for NASARIX™ Biocompatibility Program, Supporting Advancement Towards First in Human Clinical Trial
July 1, 2026
Polyrizon Makes Strong Progress: Receives Central IRB Approval for its Allergy Blocker Clinical Trial
June 29, 2026
Polyrizon Receives Notice of U.S. Patent Publication for Mucoadhesive Drug Delivery Platform
June 17, 2026
Polyrizon Advances NASARIX™ Development with Key Human Study to Characterize Nasal Residence Time and Support FDA Regulatory Pathway
June 15, 2026
Polyrizon Receives Notice of European Patent Publication for Innovative Mucoadhesive Nasal Drug Delivery Technology
June 10, 2026
Polyrizon Makes Strong Clinical Progress: Secures Three U.S. Sites for NASARIX™ Trial
June 7, 2026
Polyrizon Advances Towards Human Clinical Trials: Secures First U.S. Clinical Site for NASARIX™ Allergy Blocker Clinical Trial
May 13, 2026
Polyrizon Announces U.S. Patent Expansion for Its Intranasal Drug Delivery Platform
May 4, 2026
Polyrizon Announces Filing of European Patent Application for Its Breakthrough Drug Delivery Platform
April 27, 2026
Polyrizon Ltd. Announces Closing of $3.5 Million Registered Direct and Private Placements
April 7, 2026
Polyrizon Ltd. Announces $3.5 Million Registered Direct Offering and Private Placement
April 6, 2026
Polyrizon Provides 2025 and Recent Highlights
March 25, 2026
Polyrizon Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2025
March 24, 2026
Polyrizon Intends to Acquire up to 20% Stake in Colugo, Developer of Advanced eVTOL Drones for Defense and Urban Air Mobility Applications
March 23, 2026
Polyrizon Signs an Agreement with Leading Global Preclinical CRO as Part of Clinical Development Program
March 17, 2026
Polyrizon Announces GMP Manufacturing of Clinical Trial Material with Eurofins CDMO AmatsiAquitaine S.A.S for Planned U.S. Clinical Study
March 11, 2026
Polyrizon Announces GMP Manufacturing of Clinical Trial Material (CTM) with Eurofins CDMO AmatsiAquitaine S.A.S for Planned U.S. Clinical Study
March 9, 2026
Polyrizon Announces Successful Study of its Naloxone Formulation Demonstrating Enhanced Nasal Deposition Profile Versus Commercial Reference Product
February 26, 2026
Moonage Media Spotlights Polyrizon (Nasdaq: PLRZ): Unveils NASARIX™, Drug-Free Allergy Blocker
February 17, 2026
Polyrizon Intends to Secure Controlling Stake in Profitable Private Jet Operator
February 10, 2026
Polyrizon Signs an Agreement to Develop Intranasal Proprietary Non-Hallucinogenic Neuroplastogen Formulation
February 6, 2026
Polyrizon Intends to Acquire 51% Stake in Global Private Aviation Company
February 4, 2026
Polyrizon Advances Regulatory Path with Initiation of Usability Study Program for NASARIX™ Allergy Blocker
January 22, 2026
Polyrizon to Explore Revenue-Generating Investment Opportunities in High-Growth Sectors, Leveraging Strong Cash Position and Debt-Free Balance Sheet
January 13, 2026
Polyrizon Completes Branding Process for PL-14 Allergy Blocker with Brand Name NASARIX™
January 8, 2026
Polyrizon Announces New Pre-Clinical Results: PL-14 Demonstrates Significant Allergen-Blocking Performance Compared to a Standard Comparator
January 5, 2026
As Flu Surge Continues, Polyrizon's Nasal Spray Emerges as Potential Extra Shield Solution for Both Vaccinated and Unvaccinated
January 2, 2026